Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Deal Would Aid Afexa’s Cold-FX Expansion Plans

This article was originally published in The Tan Sheet

Executive Summary

Valeant Pharmaceuticals International’s acquisition of Afexa Health Sciences likely will boost efforts to transition Afexa’s Cold-FX from a Canadian natural health product to a U.S. pharmaceutical.
Advertisement

Related Content

In Brief
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
People In Brief
People In Brief
In Brief
Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path
Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path

Topics

Advertisement
UsernamePublicRestriction

Register

PS105281

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel